Sydafrika - engelska - South African Health Products Regulatory Authority (SAHPRA)

aurogen south africa (pty) ltd - capsules - see ingredients - each capsule contains gabapentin 100,0 mg

Sydafrika - engelska - South African Health Products Regulatory Authority (SAHPRA)

aurogen south africa (pty) ltd - capsules - see ingredients - each capsule contains gabapentin 300,0 mg

Sydafrika - engelska - South African Health Products Regulatory Authority (SAHPRA)

aurogen south africa (pty) ltd - capsules - see ingredients - each capsule contains gabapentin 400,0 mg

Sydafrika - engelska - South African Health Products Regulatory Authority (SAHPRA)

aurogen south africa (pty) ltd - capsules - see ingredients - each capsule contains gabapentin 100,0 mg

Sydafrika - engelska - South African Health Products Regulatory Authority (SAHPRA)

aurogen south africa (pty) ltd - capsules - see ingredients - each capsule contains gabapentin 300,0 mg

Sydafrika - engelska - South African Health Products Regulatory Authority (SAHPRA)

aurogen south africa (pty) ltd - capsules - see ingredients - each capsule contains gabapentin 400,0 mg

Australien - engelska - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - acalabrutinib, quantity: 100 mg - capsule, hard - excipient ingredients: iron oxide yellow; indigo carmine aluminium lake; pregelatinised starch; sodium starch glycollate type a; gelatin; shellac; silicified microcrystalline cellulose; propylene glycol; titanium dioxide; iron oxide black; magnesium stearate - calquence is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. calquence is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy.,calquence is indicated for the treatment of patients with chronic lymphocytic leukaemia(cll)/small lymphocytic lymphoma (sll).

Australien - engelska - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - duloxetine hydrochloride, quantity: 67.3 mg - capsule, enteric - excipient ingredients: gelatin; triethyl citrate; titanium dioxide; sucrose; brilliant blue fcf; hypromellose phthalate; purified talc; hypromellose; iron oxide yellow; maize starch; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia; potassium hydroxide - duloxetine capsules are indicated for the treatment of major depressive disorder (mdd). treatment of generalised anxiety disorder (gad).

Australien - engelska - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - duloxetine hydrochloride, quantity: 33.65 mg - capsule, enteric - excipient ingredients: hypromellose phthalate; triethyl citrate; brilliant blue fcf; purified talc; hypromellose; gelatin; titanium dioxide; sucrose; maize starch; propylene glycol; ethanol; indigo carmine; butan-1-ol; isopropyl alcohol; iron oxide yellow; shellac; strong ammonia solution - duloxetine capsules are indicated for the treatment of major depressive disorder (mdd). treatment of generalised anxiety disorder (gad).

Australien - engelska - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sunitinib, quantity: 50 mg - capsule - excipient ingredients: magnesium stearate; microcrystalline cellulose; gelatin; povidone; iron oxide red; mannitol; titanium dioxide; croscarmellose sodium; iron oxide black; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; ethanol; shellac; strong ammonia solution; sulfuric acid - ? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).